DDInter342 DDInter1147
Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019.
Meningococcal group C polysaccharide is group-specific polysaccharide antigens extracted and purified from *Neisseria meningitidis* serogroup C. *N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup C.
Certolizumab pegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Certolizumab pegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Certolizumab pegol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Stavudine
Certolizumab pegol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Candida albicans
Certolizumab pegol {u} may lead to a major life threatening interaction when taken with {v} Abatacept
Certolizumab pegol {u} may lead to a major life threatening interaction when taken with {v} Tildrakizumab
Certolizumab pegol may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Certolizumab pegol may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Stavudine
Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Certolizumab pegol may lead to a major life threatening interaction when taken with Abatacept
Certolizumab pegol may lead to a major life threatening interaction when taken with Tildrakizumab